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Originally thought of as a stress response end-point, the view of cellular senescence 
has since evolved into one encompassing a wide range of physiological and 
pathological functions, including both pro- and anti-tumorigenic features. It has also 
become evident that senescence is a highly dynamic and heterogenous process.  
Efforts to reconcile the beneficial and detrimental features of senescence suggest that 
physiological functions require the transient presence of senescent cells in the tissue 
microenvironment. Here, we propose the concept of a physiological ‘senescence life 










The concept of senescence has been evolving over recent decades, having originally 
been described as a stress response that leads to a persistent proliferative arrest even 
in the presence of growth factors. Since senescence can limit the propagation of 
damaged cells (which are at risk of malignant transformation), removing them from the 
proliferative pool (Campisi 2001; Lowe et al. 2004), it has therefore been considered 
to be an endogenous tumor suppressor mechanism or even a therapeutic goal, 
alternative to apoptosis. However, this is not an all-encompassing view of senescence. 
Known as the senescence-associated secretory phenotype (SASP), senescent cells 
typically secrete diverse factors, which affect the tumor microenvironment. This is also 
important for stromal cell senescence, which can be either anti- or pro-tumorigenic 
depending on the context (reviewed in (Pérez-Mancera et al. 2014)). It is perhaps safe 
to say that senescence is an autonomous tumor suppressor but a non-autonomous 
tumor ‘modulator’ (Hoare et al. 2018). 
 
Senescence has also been implicated in aging as one of the hallmarks of aging 
(López-Otín et al. 2013). It has been proposed that the age-dependent accumulation 
of senescent cells within tissue stem or progenitor cell compartments results in the 
decline of their regenerative capacity in multiple tissues (reviewed in (Sharpless and 
DePinho 2007)). These studies have provided the first functional relevance for 
senescence in aging within body organs, but more recent evidence that enforced 
killing of senescent cells in mice extends their life span has firmly established the 
causal role of senescence in aging (Baker et al. 2011; 2016). 
 




In parallel, recent evidence has described more physiological roles for senescent cells 
that extend beyond the cancer and aging contexts, with functions in shaping 
embryonic development (Storer et al. 2013; Muñoz-Espín et al. 2013; Chuprin et al. 
2013), contributing to the maturation of certain cell types (Besancenot et al. 2010; 
Helman et al. 2016) and maintaining tissue integrity in adult organisms by facilitating 
wound healing (Berg et al. 2003; Krizhanovsky et al. 2008; Jun and Lau 2010a; 
Demaria et al. 2014). Thus, despite once being considered a state of ‘functional death’, 
senescent cells do have diverse functionalities in vivo. 
 
These functions of senescent cells in tumor suppression or tissue homeostasis are 
often reinforced by or dependent on their transient presence, respectively, within the 
microenvironment, where senescent cells are eventually removed by immune cells (Ito 
et al. 2017). At least in some contexts, senescence can be seen as a progressive 
process, initiated by cellular activation, developing senescence effectors, modulation 
of the tissue microenvironment and, finally, the recruitment of immune cells to mediate 
resolution (Krizhanovsky et al. 2008). Senescence-associated disorders can perhaps 
be viewed as a consequence of a failure in the execution of the ‘senescence life cycle’ 
(Fig. 1). Misregulation of senescence within tissues can promote pathological 
conditions including cancer and other age-related disorders (Burton and Krizhanovsky 
2014; Muñoz-Espín and Serrano 2014; He and Sharpless 2017). In this review, we 
provide an overview of the relevance of senescence in tumor development, discussing 
both the autonomous and the non-autonomous aspects of senescence. We recently 
reviewed the relationship between senescence and cancer hallmarks elsewhere 
(Hoare et al. 2018). Here, we focus on the various aspects of the senescence 




response and discuss the implication of senescence in tumor development and 
treatment with particular emphasis on early stage tumors.  
 
Senescence as heterogeneous phenotype 
 
The first observation of cellular senescence in vitro was described in replicative 
exhaustion, now known to be the result of telomere shortening (Hayflick 1965; Shay 
and Wright 2000). Since then, various stress-associated inducers of ‘premature’ 
senescence have been identified, including DNA damage, oxidative stress, aberrant 
oncogene activation, and tumor suppressor gene loss (Kuilman et al. 2010; Campisi 
2013). These cellular stressors evoke persistent DNA damage signalling and 
activation of the p53/p21 and p16/pRB tumor suppressor pathways, which mediate 
entry into, and maintenance of, senescence (d'Adda di Fagagna et al. 2003; Mallette 
et al. 2007; Rodier et al. 2009; Campisi and d'Adda di Fagagna 2007). Furthermore, 
a number of additional effector programs are involved in the senescence process, and 
the concept of senescence as a collective phenotype of multiple effectors, instead of 
a single entity, has been proposed. As such, due to the lack of a single biomarker that 
is both specific and unique to senescence, it is typically characterized using a 
combination of associated cellular changes, including chromatin re-organization, the 
gene expression profile, and secretome and metabolic pathways (Salama et al. 2014; 
Kuilman et al. 2010). In light of this, using an analogy from a clinical term, entry into 
senescence can perhaps be viewed as a ‘syndrome’: the incremental acquisition of 
associated phenotypes instead of a binary event where a defined set of changes 
manifest at the same time. This is consistent with the previously proposed concept of 
the differing depths of the senescence phenotype, which is modified by important 




cellular changes that follow an initial cell cycle arrest (Baker and Sedivy 2013; Chen 
and Ozanne 2006; Passos et al. 2010; Ivanov et al. 2013). This may further explain 
the well-described phenotypic heterogeneity of senescent cells, which manifests from 
the level of gene expression, where the phenotype depends on cell-type, context, and 
nature of the upstream stressor (Passos et al. 2007; van Deursen 2014; Marthandan 
et al. 2016; Hernandez-Segura et al. 2017). Senescent cell populations have also 
been described to possess a high degree of cell-to-cell variability that exceeds that of 
quiescent cells (Wiley et al. 2017), reinforcing the heterogeneity of senescence even 
at the single cell level. 
 
Senescence in tumors 
As the induction of senescence is essentially the converse of the canonical 
unrestricted proliferation that defines cancer cells, much of the original research into 
the biology of senescence focused on its role in endogenous tumor suppression, which 
limits immortalization (telomere shortening induced senescence, see next section) and 
excessive mitotic signaling (oncogene-induced senescence, OIS).  
 
Telomere shortening 
The tumor suppressive role of senescence was originally conceived in the context of 
telomere dysfunction (Shay and Wright 2005). Replicative senescence, for instance, 
can be considered to be a counterpart of immortalization in culture. Indeed, replicative 
senescence can be, at least partially, rescued by ectopic expression of telomerase in 
culture (Bodnar et al. 1998; Vaziri and Benchimol 1998) and most (>90%) human 
cancers aberrantly upregulate telomerase (Kim et al. 1994; Shay and Bacchetti 1997; 
Jafri et al. 2016). The tumor suppressive role of telomere shortening is recapitulated 




in telomerase deficiency in various tumor-prone mouse models (González-Suárez et 
al. 2000; Blasco 2005). However, telomerase deficiency alone in mice can lead to an 
increase in spontaneous cancer incidence mainly in rapidly proliferating cell types, 
exemplified by the unusually high incidence of teratocarcinomas, probably due to 
increased genome instability, a hallmark of cancer (Rudolph et al. 1999). Importantly, 
these exceptions, where short telomeres counter-intuitively promote the incidence of 
cancer, tend to be associated with a p53 defect (Chin et al. 1999; Artandi et al. 2000).  
 
This is consistent with the view that telomere dysfunction triggers a DNA damage 
response, which activates the p53 pathway (d'Adda di Fagagna et al. 2003; Deng et 
al. 2008). The downstream effects of this pathway can be apoptosis and/or 
senescence. However, which component(s) are responsible for the tumor suppressive 
activity of short telomeres in vivo? Using a mouse model of Burkitt’s lymphoma with 
telomerase deficiency (Adams et al. 1985; Blasco et al. 1997), Feldser and Greider 
report that apoptosis is dispensable for short telomere-mediated tumor suppression. 
Provided that p53 is intact, mice remain resistant to tumor formation even following 
the blockade of apoptosis. Instead, micro-lymphomas, which stain positive for markers 
of senescence are observed, demonstrating the importance of senescence as an 
effector of tumor suppression in this context (Feldser and Greider 2007).  
 
These data suggest that the intrinsic limitation of proliferative capacity can contribute 
to a reduction in both tissue regenerative capacity and cancer initiation (Liu et al. 2011; 
Chang 2005). This appears to support the idea of a trade-off between aging and 
cancer (Kirkwood and Austad 2000; Tyner et al. 2002), although this view only 




considers the autonomous aspect of senescence (see ‘Non-autonomous effectors’ 
below) and telomere shortening is just one way to trigger senescence.  
 
Telomeres are notorious for DNA repair: it has been suggested that DNA damage in 
telomeres is effectively unrepairable, causing a persistent DNA damage response 
(DDR) and the formation of telomere-associated foci (TAF) in ageing and stress-
induced senescence (Fumagalli et al. 2012; Hewitt et al. 2012; Takai et al. 2003). This 
can occur independently of telomere length, as markers of DDR can accumulate at 
telomeres that are not yet critically shortened (Fumagalli et al. 2012). Although the 
chromosome body can also harbor persistent DNA damage after genotoxic stress 
(called DNA segments with chromatin alterations reinforcing senescence, DNA-
SCARS) (Rodier et al. 2010), live cell imaging experiments have previously suggested 
that the majority of these persistent foci are associated with telomeres (Hewitt et al. 
2012). These residual DNA damage foci appear to contribute to the maintenance of 
cell cycle arrest (Passos et al. 2010; Rodier et al. 2010) suggesting that telomere 
dysfunction-mediated senescence can also occur in contexts other than replicative 
stress. 
 
Importantly, DNA damage can induce senescence even in cancer cells in some 
contexts: called therapy-induced senescence (TIS) (Schmitt et al. 2002; Nardella et al. 
2011; Acosta and Gil 2012), and TAF formation after irradiation is not affected by 
telomerase activity (Fumagalli et al. 2012; Hewitt et al. 2012), suggesting that cancer 
cells could possibly be subjected to this mechanism. However, the anti-tumor effect of 
TIS is less evident and highly context and model dependent (Dörr et al. 2013; Tato-
Costa et al. 2016; Demaria et al. 2017; Yang et al. 2017b). This is perhaps in part due 




to the diversity of the SASP components and their pleiotropic activities, as well as the 
heterogeneity and stochasticity of cancers and their response to therapies within the 
tissue microenvironment. This point is further discussed below (see ‘Non-autonomous 
effectors’). 
 
Senescence in preneoplasia 
While replicative senescence limits cellular ‘immortalization’, an early step in 
tumorigenesis, an alternative autonomous tumor suppressive function of senescence 
can be seen in OIS, where some ‘mitogenic’ oncogenes (or loss of tumor suppressors, 
as exemplified by PTEN loss-induced cellular senescence, PICS) can paradoxically 
induce persistent proliferative arrest (Braig and Schmitt 2006; Courtois-Cox et al. 
2008; Pérez-Mancera et al. 2014). OIS was first described in human diploid fibroblasts 
in culture, where a phenotype similar to replicative senescence was observed 
following ectopic expression of constitutively active HRas (Serrano et al. 1997) or its 
downstream effectors MEK (Lin et al. 1998) or RAF1 (Zhu et al. 1998). This senescent 
phenotype is accompanied by accumulation of the tumor suppressor proteins p53 and 
p16 and a concomitant ablation of these tumor suppressors leads instead to 
transformation, supporting the notion of OIS as an intrinsic tumor suppressor 
mechanism (Lin et al. 1998; Serrano et al. 1997). In mouse models, the tumor 
suppressor p19Arf has been shown to mediate the activation of p53 in response to 
oncogenic Ras (Palmero et al. 1998). Following the description of OIS in vitro, 
senescent cells harboring oncogenic mutations were observed to accumulate in 
premalignant lesions of various tissue types both in humans and mice(Collado et al. 
2005; Michaloglou et al. 2005; Chen et al. 2005; Braig et al. 2005; Lazzerini Denchi et 
al. 2005; Collado and Serrano 2010; Narita and Lowe 2005).  





In a cell-autonomous manner, the nature of the activating oncogenic signal influences 
the balance between entry into senescence and tumorigenesis, where oncogene dose 
and the presence of other cooperating mutations have been suggested to influence 
cellular outcome (Sarkisian et al. 2007; Quintanilla et al. 1986; Tuveson et al. 2004). 
The most widely used OIS model remains the classic culture model: overexpression 
of oncogenic HRAS-G12V-induced senescence in human diploid fibroblasts (Serrano 
et al. 1997). This is highly robust and, particularly with the introduction of a 4OHT-
inducible system (Young et al. 2009), useful for procedures which require a large 
number of cells, as are often required for genomic and proteomic approaches. 
However, one inherent caveat of this model is the level of Ras, which is supra-
physiological. The natural Ras-driven tumorigenesis is typically initiated with a single 
allelic oncogenic mutation (Hobbs et al. 2016). 
 
Evidence for the notion that oncogenic dose influences cellular outcome was provided 
by earlier studies showing that mouse embryonic fibroblasts (MEFs) expressing 
endogenous level of the single allelic Kras-G12V or Kras-G12D fail to undergo 
senescence, although they were not fully transformed (Guerra et al. 2003; Tuveson et 
al. 2004). A similar insensitivity to senescence-induction by a moderate level of ectopic 
oncogenic Ras or its downstream effector, Raf was also shown in human- or 
immortalized mouse-fibroblasts (Deng et al. 2004; Sewing et al. 1997). At the same 
time, mouse models developed to recapitulate the role of oncogenic Ras mutations in 
tumorigenesis have shown that, while endogenous Kras-G12V expression leads to 
premalignant lesions in the pancreas (Hingorani et al. 2003) and preneoplastic 
hyperplasia in the lung and intestine, additional cellular alterations are typically 




required for progression to full malignancy (Tuveson et al. 2004). Furthermore, only a 
subset of cells are transformed by oncogenic KRas, even then in a highly context-
dependent manner (Jackson et al. 2001; Guerra et al. 2003; DuPage et al. 2009; Lee 
and Bae 2016). 
 
These observations suggest that a low dose of oncogenic Ras is not sufficient to 
trigger senescence programs nor malignant transformation. This was further 
supported by a mouse breast cancer model, where the level of a doxycycline-inducible 
ectopic Hras-G12V can be titrated (Sarkisian et al. 2007). Consistent with the earlier 
studies, this study also showed that high- but not low-level Ras induces senescence 
in mammary glands in vivo. In addition, while low-level Ras (comparable to the level 
expressed from the endogenous Kras-G12D allele in the mouse pancreas model 
described above) is not immediately sufficient for cancer development, the mice 
eventually develop tumors. Interestingly, these tumors (derived from low-level Ras) 
are accompanied by the spontaneous upregulation of oncogenic Ras, to a level similar 
to that of high-level Ras, which induces senescence. Furthermore, they observed 
senescent mosaicism within those low-Ras initiated tumors with spontaneous 
upregulation of oncogenic Ras. Mechanisms for the spontaneous upregulation of 
oncogenic Ras in this study were not clear, but a similar upregulation of oncogenic 
Ras during cancer development has been reported in different tumor models 
(Quintanilla et al. 1986; Finney and Bishop 1993; Aguirre et al. 2003; Junttila et al. 
2010).  
 
It is possible that, even when it is initiated by a single copy mutation, Ras activity needs 
to be increased for full malignant transformation but that this is counteracted by 




senescence programs. Perhaps the OIS culture system models a tumor suppressive 
event at this critical step of Ras-driven tumorigenesis (Fig. 2). Of note, the Ras 
pathway is regulated by diverse effectors, thus its oncogenic activity can be 
upregulated through multiple routes (Downward 2003; Calvisi et al. 2006; Courtois-
Cox et al. 2006; Shaw et al. 2007; Vandal et al. 2014). It would be important to 
determine the correlation between the level of oncogenic activity and the senescence 
phenotype during the preneoplastic stage in those genetically engineered OIS models. 
 
Autonomous senescence effectors 
As a collective phenotype made up of numerous cellular effector programs, we discuss 
autonomous and non-autonomous effectors separately, and here we focus on 
chromatin and genomic alterations as representative of the autonomous effectors 
potentially contributing to the static nature of senescence arrest.  
 
Epigenetics 
It has been proposed that senescence, unlike quiescence (a state of physiological and 
readily reversible cell cycle arrest), employs distinct alterations in the chromatin 
landscape (Parry and Narita 2016). These epigenetic and chromatin alterations occur 
at various levels: including DNA methylation, histone marks and variants, chromatin 
accessibility and non-coding RNAs (Buschbeck and Hake 2017; Pal and Tyler 2016; 
Parry and Narita 2016; Nacarelli et al. 2017). Among these, DNA methylation (5-
Methylcytosine at CpG) is, on the one hand, known as a marker of constitutive 
heterochromatin, particularly at regions with repetitive sequences. On the other hand, 
although CpG islands, which are abundant regulatory elements in mammalian 
promoters, are usually hypomethylated, the CpG islands of some genes can be 




hypermethylated in abnormal conditions: e.g. hypermethylation of CpG islands at the 
promoters of tumor suppressors leads to their silencing and promotes tumorigenesis 
(Deaton and Bird 2011).  
 
It has been long known that DNA methylation globally declines during senescence, 
forming the basis for the well-known ‘heterochromatin loss model’: the idea that a 
gradual breakdown of heterochromatin leads to the de-silencing of otherwise 
repressed genes (or non-coding RNAs), contributing to senescence and aging 
(Villeponteau 1997). However, more recent studies using next generation sequencing 
technology have revealed that the alterations in DNA methylation during senescence 
are not unidirectional. Using a model of replicative senescence in human fibroblasts, 
Cruickshanks et al. demonstrated that DNA methylation is globally reduced at 
heterochromatic regions, but focally increased at a subset of CpG islands. 
Interestingly, the pattern of hypermethylated CpG islands in replicative senescence is 
reminiscent of that of cancers, leading to the hypothesis that senescence and cancer 
share features of epigenetic change. This suggests that cells which have escaped 
from senescence would be more susceptible to subsequent transformation 
(Cruickshanks et al. 2013).  
 
This idea, that senescence-associated epigenetic alterations might contribute to a 
tumor suppressive senescence phenotype but at the same time encompass 
oncogenic properties, appears to explain well the dual effect of senescence in cancer, 
i.e. senescence as a tumor suppressor and yet also as a risk factor for cancer. This 
might also provide a partial explanation for the recent study suggesting that 
senescence escapers exhibit a stem-like signature with high tumor initiating potential 




(Milanovic et al. 2018). However, a recent study provides an alternative view. By 
directly comparing the DNA methylation profile between replicative senescent and 
transformed cells derived from the same cell line, Xie et al. identified a global reduction 
with focal increases in DNA methylation during senescence, consistent with the 
findings of the previous study. However, looking at individual genomic regions 
conversely suggested that methylation patterns evolved separately during 
tumorigenesis and progression to senescence: the former being stochastic and the 
latter being highly reproducible and thus suggesting that they are somewhat 
programmed. Based on this data, the authors propose that transformation-associated 
changes in DNA methylation status do not stem from senescence escape but rather 
reflect alterations which can be associated independently with both aging and 
increased cancer risk (Xie et al. 2018). In contrast to replicative senescence, OIS-
associated DNA methylation alterations appear to be minimal, underscoring the 
diversity of the senescence phenotype (Xie et al. 2018; Sakaki et al. 2017). Whichever 
is the case, the decline in DNA methylation of heterochromatic regions with repetitive 
sequences (e.g. transposons, satellite DNAs) in senescence or cancer potentially 
causes genome instability through a reactivation of transposons for instance. Indeed, 
expression of retrotransposable elements and satellite sequences have been shown 
to increase during replicative senescence (De Cecco et al. 2013b). 
 
In an interesting contrast to DNA methylation, the profile of DNA accessibility (a marker 
for open chromatin, which can be an indicator of developmental maturity (Stergachis 
et al. 2013)) is also altered during replicative senescence: DNA accessibility exhibits 
a global increase with focal declines (De Cecco et al. 2013a). This appears to show a 
mirror image of the DNA methylation pattern, but whether or not DNA methylation and 




chromatin accessibility are physically or functionally related has not been tested. In 
OIS too, a general increase in chromatin accessibility has been reported, and different 
oncogenes induce different profiles of accessible regions upon senescence entry 
(Parry et al. 2018) 
 
Chromatin dynamics 
In addition to the alterations to the linear structure of the genome, widespread changes 
in higher-order chromatin structure have been observed during senescence. For 
example, senescence-associated heterochromatic foci (SAHF) are readily visualized 
by microscopy as DAPI-dense foci in the nucleus (Narita et al. 2003; Zhang et al. 
2005). A number of structural and functional factors that are required for SAHF 
formation have been identified: e.g. HMGA chromatin architectural proteins and 
histone co-chaperones HIRA/ASF1a have been shown to be necessary for SAHF 
formation, whereas loss of linker histone H1 is correlated with SAHFs (Zhang et al. 
2005; Narita et al. 2006; Funayama et al. 2006). It was initially proposed that SAHFs 
are involved in the stable silencing of a subset of genes, including cell cycle genes 
(Narita et al. 2003; Sadaie et al. 2013; Zhang et al. 2007), but it is also possible that 
inter-SAHF euchromatic regions actively take part in stable gene activation. It is 
important to note that SAHF formation is model dependent, which may represent the 
heterogeneity of senescence. Interestingly, higher levels of p16 and HMGA, both of 
which are critical for SAHF formation, are correlated with the irreversibility of the 
senescence arrest (Beauséjour et al. 2003; Narita et al. 2006), reinforcing the 
existence of a spectrum of senescence, an idea associated with the ‘senescence 
syndrome’ mentioned above.   
 




In contrast to SAHF, senescence-associated distension of satellites (SADS) represent 
a distension of a-satellite and satellite II sequences, which are heterochromatic and 
normally compacted at the (peri)centromere, during senescence. SADS appear to be 
more universal than SAHFs (Swanson et al. 2013). Interestingly, both of these newly 
formed heterochromatin (SAHFs) and unfolding of constitutive heterochromatin 
(SADS) appear not to require alterations in repressive marks, H3K9me3 and 
H3K27me3 (Chandra et al. 2012; Swanson et al. 2013). Instead, these chromatin 
structural changes are mediated by a differential association with the nuclear 
membrane. In proliferating cells, heterochromatin typically localizes preferentially to 
the nuclear periphery and around the nucleolus, tethered by lamina-associated and 
nucleolus-associated chromatin domains (LADs and NADs respectively) (Padeken 
and Heun 2014). While NADs have been suggested to be conserved at least in 
replicative senescence (Dillinger et al. 2017), the level of Lamin B1 declines during 
senescence (Shimi et al. 2011; Freund et al. 2012; Sadaie et al. 2013; Shah et al. 
2013; Criscione et al. 2016). Although the loss of Lamin B1 is not sufficient for 
senescence or SAHF induction, it liberates H3K9me3-rich heterochromatin from the 
nuclear periphery and facilitates SAHF formation (Sadaie et al. 2013). These 
observations have led to the model whereby SAHFs are formed through the spatial 
re-positioning of pre-existing repressive histone marks (Chandra et al. 2012; 2015). 
Although it is not clear how Lamin B1 loss promotes SADS formation, it has been 
shown that SADS often extend along or toward the nuclear periphery and the 
researchers speculated that alterations in Lamin B1 and other structural proteins might 
contribute to this process (Swanson et al. 2013).  
 




Another consequence of Lamin B1 downregulation during senescence is 
compromised nuclear envelope integrity and the subsequent leakage of chromatin 
fragments from the nucleus into the cytoplasm as cytoplasmic chromatin fragments 
(CCFs). Although it was reported that Lamin B1 downregulation during senescence is 
mediated by RB-dependent silencing (Shimi et al. 2011), Lamin B1 is also a substrate 
of autophagic degradation (see below) (Dou et al. 2015; Lenain et al. 2015). Indeed, 
CCFs, together with Lamin B1, can be degraded by autophagy, thus this process was 
proposed as a mechanism utilized by senescent cells to remove damaged genomic 
material (Ivanov et al. 2013; Dou et al. 2015; 2017). The loss of chromatin would 
impact on the chromatin landscape, gene expression and long-term phenotype of 
senescent cells (O'Sullivan et al. 2010; Ivanov et al. 2013). However, emerging 
evidence indicates that leaked cytoplasmic DNA in turn can also trigger a discrete 
aspect of senescence, the non-autonomous activity, via activation of the cGAS/STING 
pathway which is discussed further in the next section.   
 
Non-autonomous effectors  
In addition to their essential feature (the persistency of cell cycle arrest), senescent 
cells are actively engaged in communication with other cells and the extracellular 
matrix (ECM) within the tissue microenvironment. Several modes of senescence-
associated cell-cell communication have been shown including the SASP, cell fusion 
(Chuprin et al. 2013), cytoplasmic bridges (Biran et al. 2015), cell-cell contact (Nelson 
et al. 2012; Hoare et al. 2016; Parry et al. 2018; Ito et al. 2017) and secreted 
extracellular vesicles (Takasugi et al. 2017). 
 




The SASP is the best characterised of these mechanisms (Kuilman and Peeper 2009; 
Malaquin et al. 2016), and the non-autonomous ‘functionality’ of senescent cells has 
been mostly attributed to the SASP. The fact that senescent cells secrete soluble 
factors was long known and expression of some factors, such as MMP3 and PAI1, 
had been used as markers of senescence (Krtolica et al. 2001; Parrinello et al. 2005; 
Kortlever et al. 2006). Initially, the SASP was collectively assumed to have tumor 
promoting effects (Campisi and d'Adda di Fagagna 2007), because senescent 
fibroblasts promote the tumorigenesis of co-existing premalignant epithelial cells 
(Krtolica et al. 2001). The SASP has since been demonstrated as a part of senescence 
program, itself with diverse downstream effects. For example, PAI1 was shown to be 
a downstream effector of the p53 pathway during replicative senescence, which 
contributes to cell cycle arrest; while IL6 and IL8, an inflammatory cytokine and 
chemokine respectively, reinforce senescence arrest through paracrine activities 
(Kortlever et al. 2006; Kuilman et al. 2008; Acosta et al. 2008; Wajapeyee et al. 2008). 
Increasing evidence has revealed that the SASP is a highly dynamic process, 
associated with diverse composites, regulatory mechanisms, and functionalities.  
 
Inflammatory SASP and senescence surveillance 
Among the diverse components, the best characterised factors of the SASP are of the 
pro-inflammatory type, represented by IL1, IL6 and IL8 among others. Expression of 
these inflammatory SASP components is controlled by diverse factors, such as 
epigenetic and chromatin regulators, the translation machinery, and signaling 
molecules (Tasdemir et al. 2016; Takahashi et al. 2012; Freund et al. 2011; Laberge 
et al. 2015; Herranz et al. 2015; Rodier et al. 2009; Hoare et al. 2016; Capell et al. 




2016; Aird et al. 2016; Dou et al. 2017). The central mode of SASP regulation is a 
hierarchical model, where the genes encoding the proximal inflammatory cytokines, 
such as IL1 and IL6, are induced by the inflammatory transcription factors, NFkB and 
C/EBPb, cooperatively with co-factors, such as BRD4 (Tasdemir et al. 2016). 
Importantly, these inflammatory cytokines in turn reinforce the activity of those 
transcription factors through a positive feedback loop, thus the signaling is locally 
amplified (Kuilman et al. 2008; Orjalo et al. 2009; Acosta et al. 2013; Pérez-Mancera 
et al. 2014).  
 
But how is such a signaling cascade subsequently resolved? The major outcome of 
the inflammatory SASP in vivo is not just senescence reinforcement, but also 
activation of an immune reaction (Fig. 1). The first in vivo evidence for this was derived 
from a p53-deficient liver cancer model, where cancer cells express a tetracycline-
regulable p53 RNAi (Xue et al. 2007). Restoration of endogenous p53 after the cancer 
was established led to the induction of senescence and tumor regression, which was 
not due to apoptosis but immune clearance of senescent liver tumor cells. Although 
this experiment was conducted in athymic nude mice, which are immuno-
compromised, their innate immune system is intact and sufficient for the clearance of 
senescent cells in this particular context. A follow-up study in mice lacking T and B 
cells reinforced the sufficiency of innate immune cells, in this case NK cells, in 
mediating tumor suppressive clearance of senescent cells (Iannello et al. 2013).  
 
Subsequently, a similar elimination of senescent cells by innate immune cells has 
been shown in other models, such as chronic liver damage in mice (Krizhanovsky et 




al. 2008; Lujambio et al. 2013). Krizhanovsky et al. showed that the liver damaging 
agent, CCl4, induces senescence in the liver, but those senescent cells are mainly 
hepatic stellate cells (HSCs). HSCs are fibroblast-like cells, which are normally in a 
quiescent state but become active and proliferative, followed by the development of 
senescence. Through the SASP, senescent HSCs can be eliminated by innate 
immune cells, including natural killer cells and tumor inhibiting M1-state macrophages 
(Krizhanovsky et al. 2008; Lujambio et al. 2013). Interestingly, p53-deficient HSCs 
bypass senescence and secrete factors that stimulate macrophages into a tumor 
promoting M2 state, suggesting a non-autonomous tumor suppressor activity for p53 
(Lujambio et al. 2013). This study also highlights that the SASP derived from 
senescent stromal cells has a profound impact on the tumor microenvironment. 
 
These ‘TIS’ (i.e. restoration of endogenous p53) or damage-induced senescence 
studies established the role of innate immunity in senescence clearance, but a role for 
adaptive immune components in senescence surveillance was shown in a liver OIS 
model. As shown by Kang et al. (Kang et al. 2011), ectopic expression of oncogenic 
NRas induces senescence in hepatocytes in mice and those OIS hepatocytes are 
eliminated primarily by macrophages, but this process requires activation of mutant 
NRas specific CD4+ T cells. Indeed, immune clearance of OIS hepatocytes is 
diminished when the experiment was conducted in immune-compromised mice, which 
eventually developed liver cancer (Kang et al. 2011). Interestingly, major 
histocompatibility complex class II (MHCII) is typically expressed by professional 
antigen presenting cells (APCs) but hepatocytes appear to express MHCII to directly 
present antigens (Herkel et al. 2003). Indeed, a fraction of the OIS hepatocytes appear 
to express higher level of MHCII, which, although not sufficient (i.e. professional APCs 




are necessary), is required for senescence surveillance (Kang et al. 2011). Similar 
upregulation of MHCII was reported in melanocytic OIS models. In contrast to the liver 
model, however, MHCII on OIS melanocytes appears to be sufficient for T cell 
activation (van Tuyn et al. 2017). These studies suggest that the senescence 
surveillance involves multi-levelled and distinct aspects of the immune system 
depending on the context, such as the senescence trigger and cell type. 
 
Other SASP functionality 
The functionality of the SASP is not limited to mediating immune clearance of 
senescent cells from the tissue. It also plays a role in the maintenance of tissue 
integrity. As mentioned above, upon liver damage, quiescent HSCs become activated 
and proliferate before developing senescence (Krizhanovsky et al. 2008). Activated 
HSCs produce ECM components, contributing to liver fibrosis. Importantly, the SASP 
components of senescent HSCs contains ECM degradation enzymes, thus countering 
the excessive fibrosis. Thus, tissue repair and integrity are controlled through a timely 
switch from a fibrogenic to a fibrolytic secretory program, and this switch is coupled 
with the eventual elimination of senescent cells by immune cells. A similar role for 
senescence in tissue repair and wound healing has been shown in other tissue 
damage models (liver (Kong et al. 2012; Kim et al. 2013; Borkham-Kamphorst et al. 
2014), kidney (Wolstein et al. 2010), skin (Jun and Lau 2010b; Pitiyage et al. 2011; 
Demaria et al. 2014), and heart (Zhu et al. 2013)). Notably, Krizhanovsky et al. also 
showed in the liver model (Krizhanovsky et al. 2008) that persistence of senescent 
HSCs due to the failure of immune-mediated elimination of senescent HSCs rather 
promotes liver fibrosis, reinforcing the idea of a senescence life cycle. Association 




between fibrogenic senescence and chronic tissue damage/inflammation has also 
been reported in an idiopathic pulmonary fibrosis mouse model (Schafer et al. 2017).  
  
More recently, a progressive switch of secretory factors has also been shown in the 
classical senescence model in culture, where NOTCH signaling is transiently activated 
during an early phase of senescence triggered by oncogenic HRas or DNA damage 
(Hoare et al. 2016). The NOTCH phase is correlated with a distinct secretome, 
representing TGFb and other fibrogenic factors, and subsequent downregulation of 
NOTCH signaling is required for switching to the typical inflammatory and fibrolytic 
SASP in the late phase of senescence. This is highly reminiscent of the case of HSC 
senescence (Krizhanovsky et al. 2008), but it remains to be elucidated whether or not 
Notch signaling is activated during the progressive development of HSC senescence. 
Mechanistically, it was shown that NOTCH signaling negatively regulates the 
expression of primary inflammatory cytokine production through suppressing the 
activity of the transcription factor C/EBPb . Consistently, in the liver OIS model 
described above, the inhibition of NOTCH signaling in NRas-expressing hepatocytes 
facilitates their elimination (Ito et al. 2017).  
 
A recent addition to the SASP functionality includes its role in cellular reprograming 
(reviewed in (Taguchi and Yamada 2017)). Earlier studies had shown that the 
senescence machinery autonomously serves as a barrier to reprogramming into 
induced pluripotent stem cells (iPSCs) in response to expression of the four Yamanaka 
factors (Oct3/4, Sox2, Klf4, and c-Myc) (Krizhanovsky and Lowe 2009; Li et al. 2009; 
Banito et al. 2009; Hong et al. 2009; Kawamura et al. 2009; Marión et al. 2009; Utikal 




et al. 2009). However, using mice expressing those Yamanaka factors, recent studies 
have shown that senescent cells non-autonomously facilitate the reprogramming of 
surrounding cells through an NFKB-driven secretome, particularly IL6 (Mosteiro et al. 
2016; Chiche et al. 2017). Consistently, Ritschka et al. showed that a transient or low-
level, but not prolonged, exposure to the OIS SASP promotes cellular plasticity and 
regenerative capacity in mouse skin keratinocytes (Ritschka et al. 2017). It has been 
suggested that senescence arrest in tissue stem cell or progenitor cells reduces 
regenerative capacity in some tissues (Sharpless and DePinho 2007). In contrast to 
this autonomous effect of senescence, much like the case of cellular reprograming to 
iPSC, senescent cells appear to non-autonomously contribute to maintaining the 
tissue stem cell niche.  
 
The physiological roles of senescent cells in facilitating tissue repair in response to 
injury relies on their clearance after the cessation of the wound healing processes, as 
accumulation of senescent cells conversely favour the pathogenesis of aging and age-
related disorders. Tumors have long been dubbed as “wounds that do not heal” 
(Dvorak 1986; Byun and Gardner 2013; Dvorak 2015), due to similarities between the 
phases of wound healing and that of tumor stroma formation. Through the SASP 
(derived from either tumorous or stromal senescent cells), the chronic presence of 
senescent cells within a tumor microenvironment would maintain a chronically 
inflamed microenvironment that is inherently tumorigenic (Lecot et al. 2016; Baker et 
al. 2017). The SASP also modulates other key hallmarks of cancers through locally 
facilitating vascularization (Coppé et al. 2006), epithelial-mesenchymal transition 
(Coppé et al. 2008; Kuilman et al. 2008), tumor invasion (Kim et al. 2017; He et al. 




2018) and cellular plasticity (Ritschka et al. 2017). Disruption of the senescence life 
cycle may create a tumorigenic microenvironment collectively through these SASP 
functionalities (Fig. 1). 
 
 
Upstream regulators of SASP 
The inflammatory SASP appears to be controlled through multiple effectors. For 
example, the SASP is typically promoted by a persistent DNA damage response 
(Rodier et al. 2009; Ciccia and Elledge 2010). However how the inflammatory cascade 
is initiated had not been clear until a recent series of publications showed that the 
cGAS-STING cytosolic DNA sensing pathway, described in the previous section, is a 
critical upstream event to trigger the SASP (Dou et al. 2017; Glück et al. 2017; 
Takahashi et al. 2018; Li and Chen 2018). Evolved as a defence response to viral and 
microbial infections, this pathway promotes inherent anti-tumor immunity (Deng et al. 
2014; Woo et al. 2014; Bose 2017). The cGAS-STING pathway, an intrinsic tumor 
suppressor, is deregulated in carcinomas (Xia et al. 2016) and low levels of cGAS or 
STING are correlated with poor prognosis in some cancer types (Song et al. 2017; 
Yang et al. 2017a). Interestingly, the same pathway appears to be provoked during 
senescence, sensing CCFs (Ivanov et al. 2013; Dou et al. 2015).  
 
The DNA sensor cGAS, upon binding to DNA, produces the second messenger 
cGAMP, which activates STING. This typically leads to the engagement of two 
canonical downstream pathways: A type I interferon (IFN) response mediated by IRF3 
and an inflammatory response through NFKB activation (Abe and Barber 2014; Barber 
2015). However, type I IFNs are not necessarily overrepresented in the SASP, 




depending on the cell type (Dou et al. 2017). The researchers proposed that this is in 
part due to the activation of p38MAPK (another positive regulator of the SASP (Freund 
et al. 2011)), which can inhibit STING-mediated IFN induction (Dou et al. 2017). Thus, 
the cGAS-STING pathway is critical in the activation of the NFkB-driven SASP. 
Consistently, the loss of this pathway results in reduced senescence surveillance and 
increased tumorigenesis in the liver OIS model (Glück et al. 2017; Dou et al. 2017). 
As with the inflammatory SASP, it is conceivable that prolonged activation of cGAS-
STING can also promote tumorigenesis and metastasis, possibly through chronic 
inflammation (Li and Chen 2018). Indeed, in an obesity-induced liver cancer model, 
the SASP-derived from senescent HSCs promotes liver cancer (Yoshimoto et al. 
2013) and this effect was diminished in Sting knockout mice (Dou et al. 2017). 
 
Autophagy 
It has been shown that the SASP is also controlled through macroautophagy (simply 
autophagy hereafter), another effector of senescence (Hoare et al. 2011). Autophagy, 
an evolutionarily conserved catabolic machinery, involves the formation of 
autophagosomes and their fusion to lysosomes to form autolysosomes, where 
encircled macromolecules or even organelles, are digested by lysosomal enzymes 
(Shen and Mizushima 2014). The bulk degradation of damaged macromolecules 
facilitates their turn-over and the degradation products can be an alternative energy 
source. Thus, basal autophagy is important for the quality control of cellular 
components and energy homeostasis. In addition to its basal activity, autophagy can 
also be acutely activated by not only metabolic (e.g. starvation) but also cytotoxic (e.g. 
DNA damage and oncogenic) stress. It is conceivable that stress-induced autophagy 




contributes to the degradation of damaged cellular components, but its long-term 
functional relevance is not entirely clear.  
 
One of the best-known markers of senescence is an increase in senescence-
associated b-galactosidase activity (SA-b-gal), which is derived from a lysosomal 
enzyme (Lee et al. 2006), and earlier studies have suggested that autophagy is 
activated during senescence and SA-b-gal reflects increased lysosomal mass at least 
in some contexts  (Gerland et al. 2003; Narita et al. 2011; Kurz et al. 2000). 
Functionally, it has been suggested that autophagy contributes to the senescence 
phenotype in part through modulating the SASP (Patschan et al. 2008; Young et al. 
2009). Interestingly, prolonged activation of autophagic protein degradation was 
shown to activate the anabolic counterpart of autophagy, mTOR on the surface of 
(auto)lysosomes through degradation products (i.e. amino acids) (Yu et al. 2010; 
Efeyan et al. 2012). Increased lysosomal biogenesis and compartmentalization during 
senescence have been shown in several models (Young et al. 2009; Narita et al. 2011; 
Dörr et al. 2013). It was proposed that prolonged activation of autophagy leads to the 
simultaneous activation of mTOR (which is typically regulated in the opposite direction 
to autophagy), which facilitates protein synthesis (Narita et al. 2011). How mTOR 
signaling specifically activates the SASP was not clear, but recent studies have 
proposed multiple mechanisms for this through modulating translation and the 
stabilization of mRNA molecules encoding SASP components (Herranz et al. 2015; 
Laberge et al. 2015; Tomimatsu and Narita 2015) (Fig. 3).  
 
The positive regulation of senescence by autophagy was counter-intuitive, considering 
the role of autophagy in cellular quality and fitness checks, although it is possible that 




increased autophagy activity serves as a pro-survival factor in senescent cells, which 
are known to be resistant to the cell death machinery (Dörr et al. 2013).  The relevance 
of autophagy in senescence appears to be highly context dependent (Kwon et al. 
2017). It is probably important to consider the difference between basal and stress-
induced autophagy, a lack of the former would lead to the accumulation of damaged 
macromolecules (such as p62-containing aggresomes) and damaged organelles 
(such as dysfunctional mitochondria). Thus, it is conceivable that loss of basal 
autophagy alone promotes senescence through cellular damage (Kwon et al. 2017). 
For instance, a role of basal autophagy in preventing senescence of muscle satellite 
cells thus maintaining stemness has previously been reported (García-Prat et al. 
2016). However, in addition to this autonomous activity of autophagy, autophagy 
affects a non-autonomous aspect of senescence (i.e. the SASP) in the context of 
chronic stress-induced autophagy. In addition, autophagy also contributes to other 
senescence effectors, such as (epi)genetic modulation through Lamin B1 degradation 
(Dou et al. 2015; Lenain et al. 2015). As mentioned earlier in this review, autophagy-
mediated degradation of Lamin B1 also leads to the formation of CCFs, which could 
activate the cGAS-STING-SASP axis (Fig. 3).  
 
Another layer of regulation of the SASP by autophagy was recently identified. 
Autophagy is generally considered to be a non-selective bulk degradation machinery, 
but it involves some level of selectivity through autophagy receptor proteins, such as 
p62/SQSTM1 (Komatsu and Ichimura 2010). Kang et al. have shown that the 
transcription factor GATA4 positively controls the NFkB-driven SASP (Kang et al. 
2015). They found that GATA4 is a substrate of p62-mediated selective autophagy, 
which is, in contrast to general autophagy, inhibited during senescence, indicating that 




selective autophagy can negatively regulate the inflammatory SASP. Thus overall, 
autophagy appears to affect the SASP at multiple levels in a non-unidirectional manner 




Senescence blocks the proliferation of unnecessary or unwanted cells in both 
physiological and pathological contexts. Due to this autonomous aspect, senescence 
has been proposed to be a therapeutic goal of cancer therapy. While the senescence 
arrest can be an intrinsic tumor suppressor mechanism, particularly at the early stages 
of tumorigenesis, this view turns out to be too simplistic. Senescent cells are 
metabolically active and have a profound impact, often deleterious in the long-term, 
on their neighbours through their non-autonomous activities. Interestingly, however, 
these autonomous and non-autonomous programs appear to be mechanistically 
linked. While the causal relevance of epigenetic changes during senescence remains 
elusive, the distinct epigenetic landscape in senescence has been correlated with the 
SASP (Aird et al. 2016; Tasdemir et al. 2016; Parry et al. 2018). Loss of Lamin B1 
appears to orchestrate high-order chromatin structural alterations, genomic instability, 
and the formation of CCFs, which in turn triggers the SASP (Sadaie et al. 2013; Shah 
et al. 2013; Dou et al. 2015; 2017). Autophagy, an autonomous effector by nature, 
also affects the SASP (Fig. 3). Further understanding of how the ‘irreversibility’ of cell 
cycle exit is mechanistically and functionally coupled with non-autonomous effectors 
of senescence will be of great interest. Georgilis et al. have recently identified a 
number of druggable targets, the inhibition of which can induce senescence without 
the inflammatory SASP (Georgilis et al. 2018). Such de-coupling between cell cycle 




arrest and the SASP might provide a promising therapeutic modality for pro-
senescence cancer therapy, with reduced complications from the SASP. 
 
Alternatively, senescence itself has recently been proposed to be a therapeutic target, 
rather than a goal. After the seminal work by van Deursen and colleagues, showing 
that the genetic ablation of senescent cells provides beneficial effects on health 
lifespan in mice (Baker et al. 2011), a number of small molecules that selectively kill 
senescent cells (collectively called senolytics) have been developed (Yosef et al. 
2016; Zhu et al. 2015; Baar et al. 2017; Kirkland and Tchkonia 2017; Zhu et al. 2016). 
Mostly, these reagents have been used (Demaria et al. 2017) in the context of aging 
and tissue damage (Xu et al. 2018). In the cancer context, it was shown that killing 
stromal senescent cells induced by chemotherapy reduces the associated side 
effects, such as cardiac and liver dysfunction, and general fatigue (Demaria et al. 
2017; Baar et al. 2017). 
 
However, considering the potential adverse effects of the SASP derived from TIS, 
administering ‘senolytics adjuvants’ in conjunction with pro-senescence therapy in 
cancer might be a promising approach. In fact, it was shown that targeting the 
metabolic pathways increased in senescent cells (e.g. autophagy or glucose 
utilization) in TIS lymphoma cells leads to the selective killing of TIS cells and an 
improved treatment outcome (Dörr et al. 2013). A more recent study also suggests 
that selective targeting of TIS cells using sugar-coated (thus sensitive to b-
galactosidase) nanoparticles encapsulating cytotoxic drugs is beneficial in xenograft 
models (Muñoz-Espín et al. 2018).  
 




Senescence, or even the SASP, is mostly tumor suppressive in the early stages, 
particularly when the senescent cells are eliminated by the immune system. This 
intrinsic phase might also be exploited for tumor therapy (Fig. 1). For example, it was 
shown that genetic inhibition of Notch signaling in the hepatocyte OIS model facilitates 
senescence surveillance (Hoare et al. 2016). We proposed that OIS might be most 
relevant at the stage of oncogenic ‘amplification’ (genetically or functionally) after 
somatic mutations, which are often found in normal tissues (Fig. 2) (Risques and 
Kennedy 2018). Selective targeting of cells at this stage might also be beneficial for 
tumor therapy or prevention. 
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Figure 1. Senescence ‘life cycle’
Phases of the ‘senescence life cycle’: Cells undergo senescence in response to stress in normal 
(non-cancerous) tissues. As part of the senescence programme, the secretome is modified to include 
upregulation of pro-inflammatory cytokines and chemokines which modulate the tissue microenvironment. 
This recruits immune cells and facilitates clearance of senescent cells, mediating resolution and restoring 
tissue homeostasis. Deviation from this fail-safe mechanism can instead lead to age-related pathology or 
cancer. In some cases, cells become activated / proliferative before senescence establishment, and 
senescence signaling can be locally amplified through non-autonomous activities (these points are not 







































Figure 2. OIS as a model of spontaneous upregulation of somatically mutated oncogenic 
signaling
Using oncogenic Ras as an example, an age-dependent increase of somatic mutation of oncogenes 
and their clonal expansion are common, but high-levels of oncogenic signaling is necessary for both 
OIS and full malignant transformation. Typically, spontaneous upregulation of oncogenic signaling (to 
the levels sufficient for malignancy) triggers the OIS program, which is tumor suppressive as long as the 
‘senescence life cycle’ is executed to completion. Failure to clear OIS cells can conversely be tumor 
promoting, as these cells are at risk of senescence escape having acquired tumor-facilitating cellular 































Figure 3. Multiple non-unidirectional levels through which autophagy-related processes in 
senescence affect regulation of SASP genes, often via NFkB activation. 
Activation of macroautophagy as an effector of senescence and spatial coupling of mTOR with 
autolysosomes leads to mTOR activation, which has been proposed to modulate SASP expression 
through multiple mechanisms (brown arrows). Autophagy-mediated degradation of Lamin B1 also 
promotes CCF formation, which upregulates SASP genes through the cGAS-STING pathway. This 
has been suggested to occur both by nuclear membrane blebbing (purple arrows), which shuttles 
LADs to the cytoplasm, as well as loss of nuclear envelope integrity allowing escape of chromatin 
fragments (blue arrows). However, the activation of general autophagy during senescence is 
accompanied by an inhibition of p62-mediated selective autophagy, allowing stabilisation of the 
GATA4 transcription factor, which regulates SASP genes via NFkB (green arrows). Dotted arrows 
denote physical movement, solid arrows denote signaling.  
